Form 8-K - Current report:
SEC Accession No. 0000950170-23-002132
Filing Date
2023-02-08
Accepted
2023-02-08 16:02:30
Documents
14
Period of Report
2023-02-03
Items
Item 2.02: Results of Operations and Financial Condition
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K atra-20230203.htm   iXBRL 8-K 65002
2 EX-99.1 atra-ex99_1.htm EX-99.1 362283
  Complete submission text file 0000950170-23-002132.txt   589516

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT atra-20230203.xsd EX-101.SCH 2909
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT atra-20230203_pre.xml EX-101.PRE 13504
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT atra-20230203_lab.xml EX-101.LAB 16077
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT atra-20230203_def.xml EX-101.DEF 13497
8 EXTRACTED XBRL INSTANCE DOCUMENT atra-20230203_htm.xml XML 4728
Mailing Address 2380 CONEJO SPECTRUM ST SUITE 200 THOUSAND OAKS CA 91320
Business Address 2380 CONEJO SPECTRUM ST SUITE 200 THOUSAND OAKS CA 91320 805-623-4244
Atara Biotherapeutics, Inc. (Filer) CIK: 0001604464 (see all company filings)

EIN.: 460920988 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36548 | Film No.: 23599023
SIC: 2836 Biological Products, (No Diagnostic Substances)